Oncopeptides Presents Encouraging Preliminary Phase I/ II Clinical Data with Melflufen and Dexamethasone for Patients with Relapsed and RelapsedRefractory Multiple Myeloma at the 56th ASH Annual Meeting and Exposition
Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that initial clinical data from the dose escalation part of a Phase I/II dose escalation/expansion tri...